Neuraxis (NRXS) vs Telomir Pharmaceuticals (TELO)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Neuraxis (NRXS) has outperformed Telomir Pharmaceuticals (TELO) over the past year, gaining 116.3% versus a loss of 30.3%. Neuraxis is the larger company by market cap ($85.0 million vs $84.7 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | NRXS | TELO |
|---|---|---|
| Share price | $6.77 | $1.15 |
| Market cap | $85.02M | $84.66M |
| 1-day change | -0.88% | +2.68% |
| YTD return | +49.12% | -13.53% |
| 1-year return | +116.29% | -30.30% |
| EPS (TTM) | $-0.78 | $-1.11 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $9.33 | $1.82 |
| 52-week low | $2.21 | $0.888 |
| Distance from 52-week high | -27.44% | -36.71% |
| Analyst consensus | none | none |
| Avg. price target upside | +62.48% | +247.83% |
| Average volume | 107.27K | 97.98K |
| Shares outstanding | 12.56M | 73.62M |
| Employees | 24 | — |
| Sector | Healthcare | Health Care |
| Industry | Biotechnology | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- NRXS has outperformed TELO by 146.6 percentage points over the past year.
- The two companies sit in different sectors: Neuraxis in Healthcare and Telomir Pharmaceuticals in Health Care.
About Neuraxis
NRXS stock →NeurAxis, Inc., a medical technology company, focuses on developing neuromodulation therapies to address chronic and debilitating conditions in children and adults in the United States. It offers IB-Stim, a percutaneous electrical nerve field stimulation system intended to be used in patients 8 years of age with functional abdominal pain associated with irritable bowel syndrome (IBS), functional dyspepsia (FD) and associated FD nausea symptoms.
Healthcare · Biotechnology · 24 employees
About Telomir Pharmaceuticals
TELO stock →Telomir Pharmaceuticals, Inc., a preclinical-stage biotechnology company, focuses on the development of small-molecule therapeutics designed to address upstream biological drivers of aging and age-related diseases. It is developing Telomir-1, an oral small molecule metal ion regulator designed to protect against age-related conditions, including Wilson's disease, Type 2 diabetes, age-related macular degeneration (AMD), oncology, and epigenetic regulation, as well as Alzheimer's disease and Progeria.
Health Care · Biotechnology: Pharmaceutical Preparations
NRXS vs TELO FAQ
Which is bigger, Neuraxis or Telomir Pharmaceuticals?
Neuraxis (NRXS) is larger, with a market capitalization of $85.02M compared with $84.66M for Telomir Pharmaceuticals (TELO).
Which stock has performed better over the past year, NRXS or TELO?
NRXS returned +116.29% over the past 12 months, compared with -30.30% for TELO (price return, excluding dividends). Past performance does not predict future results.
Are Neuraxis and Telomir Pharmaceuticals in the same industry?
No. Neuraxis is in the Healthcare sector, while Telomir Pharmaceuticals is in Health Care.